Camrelizumab, initially known as SHR-1210, represents a significant advancement in tumor treatment, functioning as a antibody that inhibits the programmed PD-1 receptor. This regulatory protein, expressed on lymphocytes , normally suppresses antitumor immune responses, allowing cancerous growths